Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DINAMO pediatric type 2 diabetes trial of empagliflozin and linagliptin
NL-OMON55783Phase 3Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Placebo, Linagliptin and Empagliflozin (3 arms). Primary endpoints: Change in HbA1c from baseline to Week 26 and Treatment failure by Week 26. Started Feb 2018; status: active, not recruiting.
02
Drugs
empagliflozinlinagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON55783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55783.